Damora Therapeutics, Inc.
DMRA
$20.96
$0.050.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1,171.09% | -878.77% | 25.17% | 34.74% | 40.01% |
| Total Depreciation and Amortization | 3.30% | -81.22% | -105.82% | -97.02% | -88.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4,410.58% | 3,383.87% | -32.63% | -27.93% | -17.35% |
| Change in Net Operating Assets | 2,647.62% | 788.56% | 110.27% | 99.54% | 89.87% |
| Cash from Operations | -64.52% | 63.88% | 51.40% | 55.74% | 55.13% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -100.00% | -77.38% |
| Cash from Investing | -389.57% | -249.13% | -100.00% | -100.00% | -77.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 1,846.15% | 322.40% | -70.62% | 232.61% | -109.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5,792.31% | 3,439.49% | -255.06% | -13,358.51% | -130.12% |